Clinical trial shows oral semaglutide vastly reduces heart attacks, strokes in people with type 2 diabetes

Published Date: 01 Apr 2025

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

Read Full News

Latest News

Do fatalistic attitudes affect clinical outcomes in type 2 diabetes?

University of Wisconsin-Milwaukee and University at Buffalo investigators report that diabetes fatalism is associated with lower mental health-related quality of life over 12 months in African American adults with poorly ...

Big sex differences found in how diet and insulin rewire muscle for better blood sugar

New research found that restricting calories dramatically rewires proteins in rat skeletal muscle, causing molecular changes that boost insulin sensitivity—crucial for blood sugar control in older adults, say scientists ...

Normalizing blood sugars could cut type 2 diabetes risk in half

Prediabetes has long been thought to lead to type 2 diabetes, but according to new Deakin research, for some that isn't always the case.

Why type 1 diabetes is more aggressive in young children

Scientists have made a major breakthrough in understanding why type 1 diabetes is more aggressive in young children, offering the clearest explanation to date of why the condition is particularly difficult to manage when ...

One-hour blood glucose level: A better chance to prevent diabetes

An elevated blood glucose level one hour after the oral glucose tolerance test (OGTT) signals a critical metabolic state—even before prediabetes. Affected individuals respond particularly well to lifestyle interventions. ...

Oral insulin trial marks milestone toward personalized prevention of type 1 diabetes

The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral insulin treatment. First results mark an important step toward the prevention of type 1 diabetes, ...

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

University of Wisconsin-Milwaukee and University at Buffalo investigators report that diabetes fatalism is associated with lower mental health-related quality of life over 12 months in African American adults with poorly ...

New research found that restricting calories dramatically rewires proteins in rat skeletal muscle, causing molecular changes that boost insulin sensitivity—crucial for blood sugar control in older adults, say scientists ...
HTTP error: 503

Scientists have made a major breakthrough in understanding why type 1 diabetes is more aggressive in young children, offering the clearest explanation to date of why the condition is particularly difficult to manage when ...

An elevated blood glucose level one hour after the oral glucose tolerance test (OGTT) signals a critical metabolic state—even before prediabetes. Affected individuals respond particularly well to lifestyle interventions. ...

The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral insulin treatment. First results mark an important step toward the prevention of type 1 diabetes, ...

News All Time

HTTP error: 503HTTP error: 503

Real-time glucose monitoring with professional support can improve type 1 diabetes control

People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by health care professionals in real time, via a sensor under the skin, and they received regular advice in ...

Evolutionary comparison points to pigs as superior models for human pancreas and diabetes research

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team headed by Helmholtz Munich and the German Center for Diabetes Research (DZD) has now produced a ...
HTTP error: 503

Healthy lifestyle combined with newer diabetes medications lowers cardiovascular risk, preliminary study suggests

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke or ...

Cartoon-based diabetes education can enhance children's knowledge and physical activity

Researchers at University of Tsukuba reported that using manga as an educational tool in diabetes instruction for children can be equally effective as traditional lectures in enhancing diabetes-related knowledge and engagement ...

New model shows how treating diabetes early makes a difference

Could slightly elevated blood sugar levels lead to serious health problems in the future? A single patient's question sparked nearly a decade of research leading to the development of a landmark model that could shape how ...

Researcher provides new hope in managing diabetic ketoacidosis

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels in diabetic patients and increasing exercise capacity for better health outcomes. That could be ...
HTTP error: 503

Exercise-induced vesicles help protect pancreatic cells and guard against diabetes

Exercise is known for the positive effects on metabolic diseases, partly because of the release of circulating extracellular vesicles (EVs) that mediate intercellular communication and organ crosstalk.
HTTP error: 503

Bariatric surgery in a pill bottle

More than 37 million Americans have type 2 diabetes, a chronic disorder affecting the body's ability to regulate and use sugar. According to the CDC, it's the country's seventh leading cause of death. Type 2 diabetes can ...

Early trigger of diabetic eye disease identified

A team led by UCL scientists has identified a key protein that triggers diabetic retinopathy—a condition caused by high blood sugar damaging the retina's blood vessels and a leading cause of sight loss among working-age ...

African-Caribbean ethnicity key risk factor for sight-threatening diabetic eye disease

People of African-Caribbean ethnicity with Type 2 diabetes are a third more likely to develop a condition called sight-threatening diabetic retinopathy (STDR) than other ethnic groups, according to researchers from King's.

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests

Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort have achieved remission through an intensive lifestyle intervention program, according to a study published in PLOS One by Pramod Tripathi of the Freedom ...

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot